Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Mucosal Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/mi.2009.116PMID 19794409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.

  2007cited by this paper
• Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.

  2006cited by this paper
• A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

  2006cited by this paper
• Laboratory markers in IBD: useful, magic, or unnecessary toys?

  2006cited by this paper
• Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy

  2006cited by this paper
• Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.

  2005cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea.

  2005cited by this paper
• Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.

  2004cited by this paper
• Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha.

  2004cited by this paper
• The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

  2004cited by this paper
• Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.

  2004cited by this paper
• Optimizing anti-TNF treatment in inflammatory bowel disease.

  2004cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• [Suspected cases of severe side effects after infliximab (Remicade) in Germany].

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• Validation of the interleukin‐10 knockout mouse model of colitis: antitumour necrosis factor‐antibodies suppress the progression of colitis

  2003cited by this paper
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  2003cited by this paper
• The immunological and genetic basis of inflammatory bowel disease

  2003cited by this paper
• Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Delayed Hypersensitivity Reaction and Acute Respiratory Distress Syndrome Following Infliximab Infusion

  2002cited by this paper
• Murine Monoclonal Anti-TNF Antibody Administration Has a Beneficial Effect on Inflammatory Bowel Disease That Develops in IL-10 Knockout Mice

  2002cited by this paper
• Infliximab-induced systemic lupus erythematosus.

  2002cited by this paper
• Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins*

  2002cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs*

  2001cited by this paper
• Secretion of biologically active murine interleukin-10 by Lactococcus lactis.

  2000cited by this paper
• Tumor necrosis factor: biology and therapeutic inhibitors.

  2000cited by this paper
• Oral Administration of Avian Tumor Necrosis Factor Antibodies Effectively Treats Experimental Colitis in Rats

  2000cited by this paper
• Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae.

  2000cited by this paper
• Reverse Signaling Through Transmembrane TNF Confers Resistance to Lipopolysaccharide in Human Monocytes and Macrophages1

  2000cited by this paper
• Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

  2000cited by this paper
• Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

  1999cited by this paper
• Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies

  1998cited by this paper
• Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies

  1997cited by this paper
• Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice

  1997cited by this paper
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

  1995cited by this paper
• Generation and Biological Characterization of Membrane-bound, Uncleavable Murine Tumor Necrosis Factor (*)

  1995cited by this paper
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

  1993cited by this paper
• The pathophysiology of tumor necrosis factors.

  1992cited by this paper
• A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

  1990cited by this paper
• Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.

  1989cited by this paper
• A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

  1986cited by this paper
• Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

  1982cited by this paper
• lnterleukin-10-Deficient Mice Develop Chronic Enterocolitis

  year unknowncited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Bridging discovery and therapy in precision medicine-Phage display as a catalyst for nanobody innovation: A review.

  2026cites this paper
• Nanobodies for inflammatory bowel disease: Miniaturizing solutions.

  2026cites this paper
• Receptor-targeted Lactococcus lactis mitigate Clostridioides difficile infection.

  2025cites this paper
• Nanobody therapeutics in autoimmune and immune-mediated inflammatory diseases: experimental insights and translational strategies.

  2025cites this paper
• Engineering probiotics for inflammatory bowel disease: Strategies and perspectives

  2025cites this paper
• Construction of Synthetic Probiotic Bacteria for In Situ Delivery of Anti-SARS-CoV-2 Nanobodies.

  2025cites this paper
• Research trends and hotspots of nanomaterials in inflammatory bowel disease: a bibliometric analysis.

  2025cites this paper
• Remote control designer probiotics

  2025cites this paper
• New horizons in the treatment of psoriasis: Modulation of gut microbiome

  2025cites this paper
• Exploiting the unique properties of nanobodies: enhancing therapeutics, drug delivery, and targeted diagnostics.

  2025cites this paper
• Signed, Sealed, Delivered: A Generalizable Model for Probiotic Delivery and Metabolism in the Gut

  2025cites this paper
• Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review

  2025cites this paper
• Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT

  2025cites this paper
• Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease

  2025cites this paper
• Controlled colonization of the human gut with a genetically engineered microbial therapeutic.

  2025cites this paper
• Precision Therapeutics for Inflammatory Bowel Disease Using Engineered Probiotics:Strategies and Optimization.

  2025cites this paper
• Postbiotics derived from recombinant lactic acid bacteria exhibit high IL6-binding capacity and suppress IL6-induced STAT3 signaling

  2025influential citation
• The intestinal barrier: a pivotal role in health, inflammation, and cancer.

  2025cites this paper
• A Saccharomyces boulardii synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation

  2025cites this paper
• Advanced microbiome therapeutics for oral delivery of peptides and proteins: Advances, challenges, and opportunities.

  2025cites this paper
• The Role of Gut Microbiota in Psoriasis: Current Knowledge and Emerging Therapeutic Interventions

  2024cites this paper
• From probiotic chassis to modification strategies, control and improvement of genetically engineered probiotics for inflammatory bowel disease.

  2024cites this paper
• Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases.

  2024cites this paper
• Genetically Engineered Microorganisms and Their Impact on Human Health

  2024cites this paper
• Dual engineered bacteria improve inflammatory bowel disease in mice

  2024influential citation
• Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

  2024cites this paper
• Therapeutic manipulation of the microbiome in liver disease.

  2024cites this paper
• Genetically engineered bacteria as inflammatory bowel disease therapeutics

  2024cites this paper
• Recombinant Lactococcus lactis secreting FliC protein nanobodies for resistance against Salmonella enteritidis invasion in the intestinal tract

  2024cites this paper
• Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment

  2024cites this paper
• Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions

  2024cites this paper
• Nanobody-as Versatile Tool Emerging in Autoimmune Diseases

  2024cites this paper
• Metabolic network of the gut microbiota in inflammatory bowel disease

  2024cites this paper
• Engineering bacterial warriors: harnessing microbes to modulate animal physiology.

  2024cites this paper
• Single-Domain Antibodies—Novel Tools to Study and Treat Allergies

  2024cites this paper
• Combinatorial leaky probiotic for anticancer immunopotentiation and tumor eradication

  2024cites this paper
• Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics

  2024cites this paper
• Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics

  2024cites this paper
• In Vitro Fermentation Evaluation of Engineered Sense and Respond Probiotics in Polymicrobial Communities.

  2023cites this paper
• Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives

  2023cites this paper
• From the updated landscape of the emerging biologics for IBDs treatment to the new delivery systems.

  2023cites this paper
• Controlling viral inflammatory lesions by rebalancing immune response patterns

  2023cites this paper
• Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation.

  2023cites this paper
• Advances in Targeting Drug Biological Carriers for Enhancing Tumor Therapy Efficacy.

  2023cites this paper
• L. plantarum and L. lactis as a promising agent in treatment of inflammatory bowel disease and colorectal cancer.

  2023cites this paper
• Advancement of Engineered Bacteria for Orally Delivered Therapeutics.

  2023cites this paper
• The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review

  2023influential citation
• Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut.

  2023cites this paper
• Synthetic biology: On the development of genetic circuits and their potential applications in biosciences and biofuels

  2023cites this paper
• The role of probiotics in tissue engineering and regenerative medicine.

  2023cites this paper
• Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy

  2023cites this paper
• Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies

  2023cites this paper
• Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms

  2023cites this paper
• Nanobodies in cytokine‑mediated immunotherapy and immunoimaging (Review).

  2023cites this paper
• Role of Bifidobacterium in Modulating the Intestinal Epithelial Tight Junction Barrier: Current Knowledge and Perspectives

  2023cites this paper
• Biofunctionalization of Endolysins with Oligosacharides: Formulation of Therapeutic Agents to Combat Multi-Resistant Bacteria and Potential Strategies for Their Application

  2022cites this paper
• Novel drug delivery systems for inflammatory bowel disease

  2022cites this paper
• Engineered Probiotic Lactococcus lactis for Lycopene Production against ROS Stress in Intestinal Epithelial Cells.

  2022cites this paper
• Next-Generation Probiotics for Inflammatory Bowel Disease

  2022cites this paper
• Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.

  2022cites this paper
• Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

  2022cites this paper
• Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering

  2022cites this paper
• Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis

  2022cites this paper
• Nattokinase enhances the preventive effects of Escherichia coli Nissle 1917 on dextran sulfate sodium-induced colitis in mice

  2022cites this paper
• Engineered Bacteria: General Overview as Therapeutic Agent and a Novel Drug Delivery System.

  2022cites this paper
• Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

  2022cites this paper
• Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective

  2022cites this paper
• Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice.

  2022cites this paper
• Novel technologies to characterize and engineer the microbiome in inflammatory bowel disease

  2022cites this paper
• Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody

  2022cites this paper
• Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917

  2022cites this paper
• Microbiome engineering: engineered live biotherapeutic products for treating human disease

  2022cites this paper
• Microbiome therapeutics: exploring the present scenario and challenges

  2021cites this paper
• The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics

  2021cites this paper
• Synthetic Biology: Current State and Applications

  2021cites this paper
• Designing Probiotics and Its Clinical Applications

  2021cites this paper
• Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis

  2021cites this paper
• Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases

  2021cites this paper
• Engineering living therapeutics with synthetic biology

  2021cites this paper
• Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

  2021cites this paper
• How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions

  2021cites this paper
• Stimuli-responsive engineered living materials.

  2021cites this paper
• Probiotic lactobacillus strains for enhanced health benefits (genetic engineering and microencapsulation)

  2021cites this paper
• CRAMP-encoding Lactobacillus plantarum FCQHC24 attenuates experimental colitis in mice

  2021cites this paper
• Clostridium butyricum MIYAIRI 588 Modifies Bacterial Composition under Antibiotic-Induced Dysbiosis for the Activation of Interactions via Lipid Metabolism between the Gut Microbiome and the Host

  2021cites this paper
• Direct modulation of the gut microbiota as a therapeutic approach for Alzheimer's disease.

  2021cites this paper
• In vitro inhibition of H. pylori in a preferential manner using bioengineered L. lactis releasing guided Antimicrobial peptides

  2021cites this paper
• Drug delivery to the inflamed intestinal mucosa- targeting technologies and human cell culture models for better therapies of IBD.

  2021cites this paper
• A general approach for stabilizing nanobodies for intracellular expression

  2021cites this paper
• Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products

  2021cites this paper
• Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment

  2021cites this paper
• Gut Homeostasis; Microbial Cross Talks in Health and Disease Management

  2021cites this paper
• Engineering Logical Inflammation Sensing and Secreting Circuit for Gut Modulation

  2021cites this paper
• Synthetic Biology: Current State and Applications

  2021cites this paper
• Engineered living biomaterials

  2021cites this paper
• Inflammatory bowel disease and targeted oral anti-TNFα therapy.

  2020cites this paper
• Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease.

  2020cites this paper
• Oral delivery of bacteria: Basic principles and biomedical applications.

  2020cites this paper
• Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide

  2020cites this paper
• Microbial Enzymes and Biotechniques: Interdisciplinary Perspectives

  2020cites this paper